title: Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.
abstract: Multicenter, retrospective study of standard-dose RIT in eight heavily pre-treated patients with CD20-positive follicular lymphoma who had relapsed after previous autologous bone marrow transplantation (ABMT). Patients underwent nine courses of (90)Y-ibritumomab tiuxetan (0.3 or 0.4 mCi/kg body weight). Responses included five CR, two PR, one SD and one PD. Median DFS was 12 months with median follow-up of 17 months and 1-year OS was 83% (7/8 patients). Grade 4 thrombocytopenia occurred in 7/9 treatments, with no episodes of bleeding, and only two patients received a platelet transfusion. One patient, who had 20% bone marrow involvement at the time of relapse diagnosis, presented with Grade 4 thrombocytopenia and Grade 4 neutropenia and died of septic shock 6 months after RIT. One other case of Grade 4 neutropenia, without a serious infectious syndrome, was observed. Standard-dose RIT seems feasible and potentially effective after ABMT in correctly selected patients with follicular lymphoma.
authors.affiliation: Centre Antoine Lacassagne, Nice, France. frederic.peyrade@nice.fnclcc.fr
authors.forename: Frederic
authors.initials: F
authors.lastname: Peyrade
authors.forename: Caroline
authors.initials: C
authors.lastname: Triby
authors.forename: Bohane
authors.initials: B
authors.lastname: Slama
authors.forename: Xavier
authors.initials: X
authors.lastname: Fontana
authors.forename: Remy
authors.initials: R
authors.lastname: Gressin
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Broglia
authors.forename: Gerard
authors.initials: G
authors.lastname: Lepeu
authors.forename: Patricia
authors.initials: P
authors.lastname: Carrier
authors.forename: Isabelle
authors.initials: I
authors.lastname: Peyrottes
authors.forename: Jacques
authors.initials: J
authors.lastname: Darcourt
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Bondiau
authors.forename: Antoine
authors.initials: A
authors.lastname: Thyss
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D012772:Shock, Septic / Q000209:etiology; D013921:Thrombocytopenia / Q000209:etiology; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan